StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other reports. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Cantor Fitzgerald decreased their price objective on Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Finally, Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday, September 23rd. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $6.07.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.35 on Friday. The stock’s 50 day simple moving average is $1.33 and its 200-day simple moving average is $1.35. The company has a market cap of $19.03 million, a PE ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the previous year, the business posted ($0.61) EPS. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals in the second quarter valued at $28,000. SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $34,000. AQR Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth approximately $64,000. Finally, Values First Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.